PH26516A - Novel dibenzothiazepine antipsychotic - Google Patents

Novel dibenzothiazepine antipsychotic Download PDF

Info

Publication number: PH26516A
Authority: PH; Philippines
Prior art keywords: compound; formula; salt; acid; antipsychotic
Prior art date: 1986-03-27

Application number

PH35028A

Other languages

English (en)

Inventor

Edward John Warawa

Bernard Martin Migler

Original Assignee

Ici America Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-03-27

Filing date

1987-03-16

Publication date

1992-08-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10595359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH26516(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1987-03-16 Application filed by Ici America Inc filed Critical Ici America Inc

1992-08-07 Publication of PH26516A publication Critical patent/PH26516A/en

Links

230000000561 anti-psychotic effect Effects 0.000 title description 12
YAZBBWJDISBOAL-UHFFFAOYSA-N benzo[d][1,2]benzothiazepine Chemical compound S1N=CC2=CC=CC=C2C2=CC=CC=C12 YAZBBWJDISBOAL-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 61
150000003839 salts Chemical class 0.000 claims description 29
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 16
238000000034 method Methods 0.000 claims description 13
208000013403 hyperactivity Diseases 0.000 claims description 11
241000124008 Mammalia Species 0.000 claims description 10
239000002253 acid Substances 0.000 claims description 7
239000000203 mixture Substances 0.000 claims description 7
208000028017 Psychotic disease Diseases 0.000 claims description 4
231100000252 nontoxic Toxicity 0.000 claims description 3
230000003000 nontoxic effect Effects 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims 2
UELITFHSCLAHKR-UHFFFAOYSA-N acibenzolar-S-methyl Chemical compound CSC(=O)C1=CC=CC2=C1SN=N2 UELITFHSCLAHKR-UHFFFAOYSA-N 0.000 claims 1
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
238000006243 chemical reaction Methods 0.000 description 30
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
150000003840 hydrochlorides Chemical class 0.000 description 20
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
238000010992 reflux Methods 0.000 description 16
230000000694 effects Effects 0.000 description 14
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
241000282693 Cercopithecidae Species 0.000 description 10
241000699670 Mus sp. Species 0.000 description 10
241000700159 Rattus Species 0.000 description 10
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 10
208000012661 Dyskinesia Diseases 0.000 description 9
-1 THIAZEPINE COMPOUNDS Chemical class 0.000 description 9
206010043118 Tardive Dyskinesia Diseases 0.000 description 9
JSYGRUBHOCKMGQ-UHFFFAOYSA-N dichloramine Chemical compound ClNCl JSYGRUBHOCKMGQ-UHFFFAOYSA-N 0.000 description 9
239000000047 product Substances 0.000 description 9
239000000243 solution Substances 0.000 description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
239000000164 antipsychotic agent Substances 0.000 description 8
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
238000001914 filtration Methods 0.000 description 8
238000004809 thin layer chromatography Methods 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
208000010118 dystonia Diseases 0.000 description 7
150000003951 lactams Chemical class 0.000 description 7
CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 7
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
230000009194 climbing Effects 0.000 description 6
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 6
229960004170 clozapine Drugs 0.000 description 6
229940079593 drug Drugs 0.000 description 6
239000003814 drug Substances 0.000 description 6
230000000142 dyskinetic effect Effects 0.000 description 6
238000010438 heat treatment Methods 0.000 description 6
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
239000002904 solvent Substances 0.000 description 6
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 5
241000282668 Cebus Species 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 5
229940025084 amphetamine Drugs 0.000 description 5
229910052801 chlorine Inorganic materials 0.000 description 5
229960003878 haloperidol Drugs 0.000 description 5
239000012074 organic phase Substances 0.000 description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
230000004044 response Effects 0.000 description 5
239000000741 silica gel Substances 0.000 description 5
229910002027 silica gel Inorganic materials 0.000 description 5
239000007787 solid Substances 0.000 description 5
229960002784 thioridazine Drugs 0.000 description 5
230000008485 antagonism Effects 0.000 description 4
230000001090 anti-dopaminergic effect Effects 0.000 description 4
229960004046 apomorphine Drugs 0.000 description 4
239000002585 base Substances 0.000 description 4
230000001143 conditioned effect Effects 0.000 description 4
229960003638 dopamine Drugs 0.000 description 4
QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
229910000029 sodium carbonate Inorganic materials 0.000 description 4
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 3
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
208000007101 Muscle Cramp Diseases 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
208000005392 Spasm Diseases 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
150000001450 anions Chemical class 0.000 description 3
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 3
125000004429 atom Chemical group 0.000 description 3
239000002981 blocking agent Substances 0.000 description 3
230000037396 body weight Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
239000000460 chlorine Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000002274 desiccant Substances 0.000 description 3
UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 description 3
238000001035 drying Methods 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
239000001530 fumaric acid Substances 0.000 description 3
229910052736 halogen Inorganic materials 0.000 description 3
230000002140 halogenating effect Effects 0.000 description 3
150000002367 halogens Chemical class 0.000 description 3
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 3
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 3
230000035939 shock Effects 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000008096 xylene Substances 0.000 description 3
DGBISJKLNVVJGD-UHFFFAOYSA-N 2-phenylsulfanylaniline Chemical compound NC1=CC=CC=C1SC1=CC=CC=C1 DGBISJKLNVVJGD-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
241000282414 Homo sapiens Species 0.000 description 2
208000015592 Involuntary movements Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
206010034010 Parkinsonism Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
229910001508 alkali metal halide Inorganic materials 0.000 description 2
150000008045 alkali metal halides Chemical class 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
125000004414 alkyl thio group Chemical group 0.000 description 2
150000001448 anilines Chemical class 0.000 description 2
229940005529 antipsychotics Drugs 0.000 description 2
239000000010 aprotic solvent Substances 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000012043 crude product Substances 0.000 description 2
238000001514 detection method Methods 0.000 description 2
ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000000284 extract Substances 0.000 description 2
239000012458 free base Substances 0.000 description 2
ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
239000005457 ice water Substances 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000011630 iodine Substances 0.000 description 2
230000002045 lasting effect Effects 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
238000003760 magnetic stirring Methods 0.000 description 2
239000011976 maleic acid Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
239000003495 polar organic solvent Substances 0.000 description 2
229920000137 polyphosphoric acid Polymers 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
235000009518 sodium iodide Nutrition 0.000 description 2
239000000725 suspension Substances 0.000 description 2
NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical compound S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 description 2
150000003568 thioethers Chemical class 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
FLNQAPQQAZVRDA-UHFFFAOYSA-N 1-(2-(2-Hydroxyethoxy)ethyl)piperazine Chemical compound OCCOCCN1CCNCC1 FLNQAPQQAZVRDA-UHFFFAOYSA-N 0.000 description 1
HUTXVUPGARJNHM-UHFFFAOYSA-N 1-(2-chloroethoxy)ethanol Chemical compound CC(O)OCCCl HUTXVUPGARJNHM-UHFFFAOYSA-N 0.000 description 1
PFCBGPOWBVNNMA-UHFFFAOYSA-N 2-(1-piperazin-1-ylethoxy)ethanol Chemical compound OCCOC(C)N1CCNCC1 PFCBGPOWBVNNMA-UHFFFAOYSA-N 0.000 description 1
CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 1
ZFOZNNFYECYUQB-UHFFFAOYSA-N 6-chlorobenzo[b][1,4]benzothiazepine Chemical compound ClC1=NC2=CC=CC=C2SC2=CC=CC=C12 ZFOZNNFYECYUQB-UHFFFAOYSA-N 0.000 description 1
206010001540 Akathisia Diseases 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
102000015554 Dopamine receptor Human genes 0.000 description 1
108050004812 Dopamine receptor Proteins 0.000 description 1
208000014094 Dystonic disease Diseases 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
241000282695 Saimiri Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
206010044074 Torticollis Diseases 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001351 alkyl iodides Chemical class 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000002932 anti-schizophrenic effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
CXWQXGNFZLHLHQ-DPFCLETOSA-N apomorphine hydrochloride Chemical compound [H+].[H+].O.[Cl-].[Cl-].C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 CXWQXGNFZLHLHQ-DPFCLETOSA-N 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
239000003874 central nervous system depressant Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229960001076 chlorpromazine Drugs 0.000 description 1
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000013329 compounding Methods 0.000 description 1
150000008533 dibenzodiazepines Chemical class 0.000 description 1
150000008509 dibenzothiazepines Chemical class 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000003210 dopamine receptor blocking agent Substances 0.000 description 1
239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000000632 dystonic effect Effects 0.000 description 1
238000000835 electrochemical detection Methods 0.000 description 1
239000012259 ether extract Substances 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
MSQACBWWAIBWIC-UHFFFAOYSA-N hydron;piperazine;chloride Chemical compound Cl.C1CNCCN1 MSQACBWWAIBWIC-UHFFFAOYSA-N 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
238000007726 management method Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
125000005905 mesyloxy group Chemical group 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
239000003176 neuroleptic agent Substances 0.000 description 1
230000000701 neuroleptic effect Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229940054010 other antipsychotics in atc Drugs 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
238000003359 percent control normalization Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
FWULFEHVLSQUBD-UHFFFAOYSA-N phenyl n-(2-phenylsulfanylphenyl)carbamate Chemical compound C=1C=CC=CC=1OC(=O)NC1=CC=CC=C1SC1=CC=CC=C1 FWULFEHVLSQUBD-UHFFFAOYSA-N 0.000 description 1
UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000000698 schizophrenic effect Effects 0.000 description 1
241000894007 species Species 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
229940125725 tranquilizer Drugs 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D281/16—[b, f]-condensed
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Neurosurgery (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Anesthesiology (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PH35028A 1986-03-27 1987-03-16 Novel dibenzothiazepine antipsychotic PH26516A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB868607684A GB8607684D0 (en)	1986-03-27	1986-03-27	Thiazepine compounds

Publications (1)

Publication Number	Publication Date
PH26516A true PH26516A (en)	1992-08-07

Family

ID=10595359

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH35028A PH26516A (en)	1986-03-27	1987-03-16	Novel dibenzothiazepine antipsychotic

Country Status (31)

Country	Link
US (1)	US4879288A (de)
EP (1)	EP0240228B1 (de)
JP (1)	JPH064606B2 (de)
KR (1)	KR900001868B1 (de)
AR (1)	AR242198A1 (de)
AT (1)	ATE58132T1 (de)
AU (1)	AU593336B2 (de)
BG (1)	BG61365B2 (de)
CA (1)	CA1288428C (de)
CY (2)	CY1706A (de)
DD (1)	DD259403A5 (de)
DE (3)	DE10075017I1 (de)
DK (1)	DK174618B1 (de)
ES (1)	ES2019379T4 (de)
FI (1)	FI86059C (de)
GB (2)	GB8607684D0 (de)
GR (1)	GR3001061T3 (de)
HK (1)	HK85393A (de)
HU (1)	HU201062B (de)
IE (1)	IE59864B1 (de)
IL (1)	IL81923A (de)
LU (1)	LU90593I2 (de)
MW (1)	MW2087A1 (de)
NL (1)	NL980022I2 (de)
NO (2)	NO168771C (de)
NZ (1)	NZ219788A (de)
PH (1)	PH26516A (de)
PT (1)	PT84569B (de)
ZA (1)	ZA871940B (de)
ZM (1)	ZM2987A1 (de)
ZW (1)	ZW5787A1 (de)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8705574D0 (en) *	1987-03-10	1987-04-15	Ici Plc	Preparation of thiazepine compound
DE3827447A1 (de) *	1988-08-12	1990-04-26	Basf Ag	Polyazofarbstoffe und deren zwischenprodukte
US5312819A (en) *	1990-08-20	1994-05-17	Sandoz Ltd.	Pharmaceutical compositions comprising clozapine and a radical scavenger
GB9109557D0 (en) *	1991-05-02	1991-06-26	Wellcome Found	Chemical compounds
US5240927A (en) *	1992-05-19	1993-08-31	Hoechst-Roussel Pharmaceuticals Incorporated	Benzo[β]thiophen-3-yl piperazines as antipsychotic agents
JP2000507544A (ja) *	1996-03-25	2000-06-20	イーライ・リリー・アンド・カンパニー	痛みの治療方法
US5948437A (en) *	1996-05-23	1999-09-07	Zeneca Limited	Pharmaceutical compositions using thiazepine
GB9611328D0 (en) *	1996-05-31	1996-08-07	Zeneca Ltd	Pharmaceutical compositions
GB9716161D0 (en) *	1997-08-01	1997-10-08	Zeneca Ltd	Process
GB9922271D0 (en) *	1999-09-21	1999-11-17	Zeneca Ltd	Formulation
SE0003126D0 (sv) *	2000-09-05	2000-09-05	Astrazeneca Ab	Method of treatment
DE60125062T2 (de) *	2000-12-20	2007-05-31	Astrazeneca Ab	Quetiapin zur Behandlung der Dyskinesie in nicht-psychotischen Patienten
ES2284830T3 (es)	2001-02-06	2007-11-16	Astrazeneca Ab	Uso de quetiapina para el tratamiento de la cocaina.
EP1795199A3 (de) *	2001-02-06	2007-07-25	AstraZeneca AB	Quetiapin für die Behandlung von Substanzabhängigkeit oder Substanzmissbrauch
US20040023951A1 (en) *	2001-06-18	2004-02-05	Bymaster Franklin Porter	Combination therapy for treatment of psychoses
SE0102855D0 (sv) *	2001-08-27	2001-08-27	Astrazeneca Ab	Method of treatment
PT1458888E (pt) *	2001-12-10	2011-06-01	Novartis Ag	Métodos para tratar a psicose e a esquizofrenia baseados em polimorfismos no gene do cntf
IL163666A0 (en)	2002-02-22	2005-12-18	New River Pharmaceuticals Inc	Active agent delivery systems and methods for protecting and administering active agents
JP4414237B2 (ja) *	2002-03-20	2010-02-10	テバファーマシューティカルインダストリーズリミティド	ケチアピンヘミフマレートの結晶形
KR100707050B1 (ko)	2002-11-28	2007-04-13	에스케이 주식회사	10Ｈ-디벤조[ｂ,ｆ][1,4]티아제핀-11-온의 제조방법
SI1583542T1 (sl) *	2003-01-14	2008-12-31	Gilead Sciences Inc	Sestavki in postopki za kombinacijsko antivirusnoterapijo
EP1495008A1 (de) *	2003-02-22	2005-01-12	Teva Pharmaceutical Industries Limited	Synthese von quetiapin und seiner pharmazeutisch verträglichen salze
TR200503401T1 (tr) *	2003-03-03	2008-03-21	Hetero Drugs Limited	Kuetiapin (Quetiapine) Fumarat'ın yeni polimorfları
US7053115B2 (en) *	2003-04-07	2006-05-30	Hetero Drugs Limited	Crystalline form of dorzolamide hydrochloride
EP1633400A2 (de) *	2003-05-16	2006-03-15	Pfizer Products Inc.	Therapeutische kombinationen von atypischen antipsychotika mit gaba-modulatoren, anticonvulsiva oder benzodiazepinen
MXPA05013869A (es) *	2003-07-02	2006-02-28	Astrazeneca Ab	Metabolito de quetiapina.
US20090093460A1 (en) *	2003-07-02	2009-04-09	Astrazeneca Ab	Compositions
US20090093461A1 (en) *	2003-07-02	2009-04-09	Astrazeneca Ab	Methods of Treating Anxiety and Mood Disorders
US20060217365A1 (en) *	2003-07-02	2006-09-28	Astrazeneca Ab	Method of treating mood disorders
US20060217367A1 (en) *	2004-07-01	2006-09-28	Astrazeneca Ab	Method of treating anxiety disorders
US20060252743A1 (en) *	2005-01-07	2006-11-09	Astrazeneca Ab	Method of treating sleep disorders
US20060217366A1 (en) *	2003-07-02	2006-09-28	Astrazeneca Ab	Method of treating schizophrenia and other disorders
US20070117789A1 (en) *	2005-11-18	2007-05-24	Astrazeneca Ab	Method of treatment
US20060229292A1 (en) *	2005-01-07	2006-10-12	Astrazeneca Ab	Method of treating childhood disorders
ES2223294B2 (es) *	2003-08-08	2005-10-01	Vita Cientifica, S.L.	Procedimiento de preparacion de un compuesto farmaceuticamente activo.
US20050080072A1 (en) *	2003-09-01	2005-04-14	Orchid Chemicals & Pharmaceuticals Ltd.	Process for the preparation of a thiazepine derivative
EP1664009B1 (de)	2003-09-23	2011-01-19	Fermion Oy	Verfahren zur herstellung von quetiapin
EP1689367A1 (de) *	2003-10-21	2006-08-16	Actavis Group HF	Pharmazeutische formulierungen mit quetiapin
GB0326148D0 (en)	2003-11-10	2003-12-17	Lilly Co Eli	Morpholine derivatives
WO2005063254A2 (en)	2003-12-22	2005-07-14	Acadia Pharmaceuticals Inc.	Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20050171088A1 (en) *	2004-01-30	2005-08-04	Astrazeneca Ab	Treatment of psychoses with dibenzothiazepine antipsychotic
US20050233010A1 (en) *	2004-04-19	2005-10-20	Satow Philip M	Lithium combinations, and uses related thereto
MXPA06013163A (es) *	2004-05-11	2007-02-13	Pfizer Prod Inc	Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b.
MY147767A (en) *	2004-06-16	2013-01-31	Janssen Pharmaceutica Nv	Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AR049646A1 (es) *	2004-06-16	2006-08-23	Janssen Pharmaceutica Nv	Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
KR101038389B1 (ko) *	2004-06-23	2011-06-01	에스케이바이오팜 주식회사	11-(4-[2-(2-히드록시에톡시)에틸]-1-피페라지닐)-디벤조[ｂ,ｆ][1,4]티아제핀의 제조방법
TW200616608A (en) *	2004-07-09	2006-06-01	Forest Laboratories	Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
MX2007002309A (es) *	2004-08-24	2007-10-08	Johnson & Johnson	Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos.
WO2006027789A1 (en) *	2004-09-08	2006-03-16	Jubilant Organosys Limited	PROCESS FOR PRODUCING 11-[4-[2-(2-HYDROXYETHOXY)ETHYL]-1-PIPERAZINYL]DIBENZO[b,f][1,4]THIAZEPINE AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
US20060063927A1 (en) *	2004-09-22	2006-03-23	Olga Etlin	Processes for preparing quetiapine and salts thereof
WO2006035293A1 (en) *	2004-09-27	2006-04-06	Ranbaxy Laboratories Limited	Polymorphic forms of quetiapine hemifumarate
WO2006056772A2 (en) *	2004-11-23	2006-06-01	Pliva Hrvatska D.O.O.	Salts of quetiapine
EP1838325A1 (de) *	2005-01-07	2007-10-03	AstraZeneca AB	Neue verwendung von piperazin-1-yldibenzo [b,f][1,4]thiazepin oder seines pharmazeutisch annehmbaren salzes und orale pharmazeutische zusammensetzungen
EP1841751A1 (de) *	2005-01-24	2007-10-10	IPCA Laboratories Limited	Grosstechnische herstellung von 11-[4-{2-(2-hydroxyethoxy)ethyl}-1-piperazinyl]dibenzo[b,f]-[1,4]thiazepin
BRPI0606932A2 (pt) *	2005-01-26	2009-07-28	Elan Pharma Int Ltd	formulação, forma de dosagem, e, uso de uma quantidade terapeuticamente efetiva de uma formulação
ES2234447B1 (es) *	2005-03-07	2006-03-01	Union Quimico-Farmaceutica S.A.	Procedimiento para la obtencion de un derivado de 11-(4-sustituido-1-piperazinil)dibenzo(b,f)(1,4)tiazepina.
EP1863485A2 (de) *	2005-03-18	2007-12-12	Abbott Laboratories	Alpha7-neuronaler nikotin-rezeptorligand und antipsychotische zusammensetzungen
US7488821B2 (en) *	2005-04-04	2009-02-10	Divi's Laboratories Limited	Polymorph of Quetiapine fumarate and a process for its preparation
US7687622B2 (en) *	2005-04-14	2010-03-30	Teva Pharmaceutical Industries, Ltd	Process for preparing quetiapine fumarate
US8048876B2 (en)	2005-04-21	2011-11-01	Medichem S.A.	Process for preparing quetiapine and quetiapine fumarate
CA2605447A1 (en) *	2005-04-22	2006-11-02	Wyeth	Therapeutic combinations for the treatment or prevention of psychotic disorders
MX2007014613A (es) *	2005-05-20	2008-04-02	Johnson & Johnson	Procedimiento para la preparacion de derivados de sulfamida.
US20070072840A1 (en) *	2005-05-30	2007-03-29	Pandya Bhargav	Polymorphic forms of quetiapine
TWI471145B (zh) *	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
TWI375560B (en) *	2005-06-13	2012-11-01	Gilead Sciences Inc	Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
WO2007004234A1 (en) *	2005-07-04	2007-01-11	Usv Limited	A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE
GB0516603D0 (en) *	2005-08-12	2005-09-21	Sandoz Ag	Processes for the preparation of organic compounds useful as serotonin receptor antagonists
WO2007036599A1 (en)	2005-09-30	2007-04-05	Fermion Oy	New crystallization process of quetiapine hemifumarate
AU2006311577B2 (en)	2005-11-09	2013-02-07	Zalicus Inc.	Methods, compositions, and kits for the treatment of medical conditions
WO2009151393A1 (en) *	2008-06-14	2009-12-17	Astrazeneca Ab	Novel derivatives of 11-piperazin-l-yldibenzo [b,f] [l,4] thiazepine for treating at least one syndrome or condition associated with schizophrenia and other psychotic disorders
TW200735878A (en) *	2005-11-18	2007-10-01	Astrazeneca Ab	Pharmaceutical compositions
US8389510B2 (en) *	2005-11-18	2013-03-05	Astrazeneca Ab	Crystalline forms
WO2009151392A1 (en) *	2008-06-14	2009-12-17	Astrazeneca Ab	Novel derivatives of 11-piperazin-l-yldibenzo [b,f] [1,4] thiazepine for treating at least one syndrome or condition associated with schizophrenia and other psychotic disorders
US8497298B2 (en) *	2005-12-19	2013-07-30	Janssen Pharmaceutica Nv	Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155824A1 (en) *	2005-12-19	2007-07-05	Smith-Swintosky Virginia L	Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US20070155823A1 (en) *	2005-12-19	2007-07-05	Smith-Swintosky Virginia L	Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8691867B2 (en) *	2005-12-19	2014-04-08	Janssen Pharmaceutica Nv	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8716231B2 (en)	2005-12-19	2014-05-06	Janssen Pharmaceutica Nv	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070155827A1 (en) *	2005-12-19	2007-07-05	Smith-Swintosky Virginia L	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8937096B2 (en)	2005-12-19	2015-01-20	Janssen Pharmaceutica Nv	Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
AR058389A1 (es) *	2005-12-19	2008-01-30	Janssen Pharmaceutica Nv	Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US20100178333A1 (en) *	2006-01-25	2010-07-15	Astron Research Limited	Sustained release dosage form of phenothiazine derivatives containing channelizer
US20070191460A1 (en) *	2006-02-15	2007-08-16	Smith-Swintosky Virginia L	Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
US20070191451A1 (en) *	2006-02-15	2007-08-16	Smith-Swintosky Virginia L	Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
US20070191450A1 (en) *	2006-02-15	2007-08-16	Smith-Swintosky Virginia L	Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
US20070191474A1 (en) *	2006-02-15	2007-08-16	Smith-Swintosky Virginia L	Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
WO2007102074A2 (en) *	2006-03-07	2007-09-13	Cadila Healthcare Limited	Salts of quetiapine
WO2007137167A2 (en) *	2006-05-19	2007-11-29	Janssen Pharmaceutica N.V.	Co-therapy for the treatment of epilepsy
ATE523602T1 (de)	2006-06-12	2011-09-15	Hadasit Med Res Service	Mit durch antipsychotika induzierten extrapyramidalen symptomen assoziierte rgs2- genotypen
US20080004260A1 (en) *	2006-06-29	2008-01-03	Transcept Pharmaceuticals, Inc.	Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
CZ300451B6 (cs) *	2006-07-03	2009-05-20	Farmak, A. S.	Zpusob prípravy solí 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanolu (quetiapinu) a jejich cištení
WO2008047340A1 (en) *	2006-10-19	2008-04-24	Mor Research Applications Ltd.	Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders
WO2008066620A2 (en) *	2006-10-20	2008-06-05	Concert Pharmaceuticals Inc.	Dibenzothiazepine derivatives
CN101610774B (zh) *	2006-11-03	2012-04-04	萨斯喀彻温大学	治疗脱髓鞘疾病的方法
PT103884A (pt)	2006-11-17	2008-05-19	Astrazeneca Ab	Composições de libertação prolongada e métodos para a sua preparação
HUE032743T2 (en)	2006-11-22	2017-10-30	Clinical Res Ass Llc	A method for treating Down syndrome, fragilis X syndrome and autism
CN101616585A (zh) *	2006-12-20	2009-12-30	阿斯利康(瑞典)有限公司	化合物及其用途
JP2010531292A (ja) *	2006-12-20	2010-09-24	アストラゼネカ・アクチエボラーグ	化合物及びその使用
WO2008110337A2 (en)	2007-03-09	2008-09-18	Synthon B.V.	Pharmaceutical composition of quetiapine fumarate
CN100569761C (zh) *	2007-04-18	2009-12-16	湖南洞庭药业股份有限公司	制备药物纯富马酸喹硫平的生产方法
WO2009004480A2 (en) *	2007-05-07	2009-01-08	Actavis Group Ptc Ehf	Quetiapine salts and their polymorphs
HU230144B1 (hu) *	2007-06-12	2015-09-28	Richter Gedeon Nyrt.	Eljárás quetiapin előállítására
US20090082334A1 (en) *	2007-09-25	2009-03-26	Protia, Llc	Deuterium-enriched quetiapine
US20090220593A1 (en) *	2008-01-29	2009-09-03	Gulati Inder	Extended release dosage forms of quetiapine
CA2711395A1 (en) *	2008-01-31	2009-08-06	Fermion Oy	A process for the preparation of quetiapine
CA2716080C (en)	2008-02-20	2016-12-13	Targia Pharmaceuticals	Cns pharmaceutical compositions and methods of use
US20090247617A1 (en) *	2008-03-26	2009-10-01	Abdel-Magid Ahmed F	Process for the preparation of benzo-fused heteroaryl sulfamates
US20090264408A1 (en) *	2008-04-17	2009-10-22	Gulati Inder	Extended release dosage forms of quetiapine
WO2009128058A1 (en)	2008-04-18	2009-10-22	UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al	Psycho-pharmaceuticals
KR20110019781A (ko)	2008-06-20	2011-02-28	아스트라제네카 아베	디벤조티아제핀 유도체 및 그의 용도
AU2009271362B2 (en)	2008-06-23	2014-03-13	Janssen Pharmaceutica Nv	Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
WO2009156889A1 (en) *	2008-06-25	2009-12-30	Pfizer Inc.	Diaryl compounds and uses thereof
WO2010001413A2 (en) *	2008-07-01	2010-01-07	Lupin Limited	Sustained release pharmaceutical compositions comprising quetiapine
US8815939B2 (en) *	2008-07-22	2014-08-26	Janssen Pharmaceutica Nv	Substituted sulfamide derivatives
EP2299983A4 (de) *	2008-07-24	2012-10-10	Handa Pharmaceuticals Llc	Stabilisierte atypische antipsychotische formulierung
EA018638B1 (ru) *	2008-08-01	2013-09-30	Крка, Товарна Здравил, Д. Д., Ново Место	Композиция кветиапина
EP2153834A3 (de)	2008-08-07	2010-02-24	Farmaprojects, S.A.	Pharmazeutische Zusammensetzungen mit anhaltender Freisetzung, die Quetiapinsalze umfassen
DE102008046650A1 (de) *	2008-09-10	2010-03-11	Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg	Quetiapin enthaltende Retardtablette
JP2012502915A (ja)	2008-09-15	2012-02-02	バイオビスタインコーポレイテッド	てんかんを治療する組成物及び方法
EP2373319B1 (de) *	2009-01-05	2013-07-31	Torrent Pharmaceuticals Limited	Pharmazeutische zusammensetzung aus quetiapin mit verzögerter freisetzung und verfahren zu ihrer herstellung
WO2010089259A2 (en)	2009-02-04	2010-08-12	Woerwag R&D Gmbh	Sustained release composition containing quetiapine
JP2012519683A (ja)	2009-03-04	2012-08-30	ランバクシーラボラトリーズリミテッド	フマル酸クエチアピンの調製方法
EP2233130A1 (de)	2009-03-23	2010-09-29	Genepharm (Europe) Trading Limited	Orale Zusammensetzung mit verzögerter Freisetzung eines Antipsychotikums
US20100298397A1 (en) *	2009-05-19	2010-11-25	Singh Nikhilesh N	Method of treatment of obsessive compulsive disorder with ondansetron
US8252801B1 (en)	2009-06-03	2012-08-28	Abbott Laboratories	Treatment of schizophrenia and related disorders
CA2785846C (en)	2009-12-31	2015-07-07	Kempharm, Inc.	Amino acid conjugates of quetiapine, process for making and using the same
SI2544536T1 (sl) *	2010-03-11	2019-03-29	Kempharm, Inc.	Maščobno kislinski konjugati kvetiapina proces za njih izdelavo in uporabo
HRP20240109T1 (hr)	2010-08-23	2024-03-29	Alkermes Pharma Ireland Limited	Postupci za liječenje povećanja tjelesne težine induciranog antipsihoticima
TR201008261A1 (tr)	2010-10-08	2012-04-24	Sanovel İlaç San. Ve Ti̇c. A.Ş.	Kontrollü salım gerçekleştiren ketiapin formülasyonları
US8741888B2 (en)	2010-11-09	2014-06-03	Carl A. Forest	Sleep aid composition and method
JP5916746B2 (ja)	2010-11-15	2016-05-11	エージンバイオ，インコーポレイテッド	認知障害を処置するためのピリダジン誘導体、組成物、および方法
TR201104977A1 (tr)	2011-05-23	2012-12-21	Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇	Kontrollü salım gerçekleştiren kaplamaya sahip ketiapin formülasyonu.
WO2013074048A2 (en)	2011-08-08	2013-05-23	Mahmut Bilgic	Tablet forms comprising quetiapine fumarate
CN102391208A (zh) *	2011-10-25	2012-03-28	湖南洞庭药业股份有限公司	富马酸喹硫平的新晶形i及其制备方法
WO2013095312A1 (en)	2011-12-19	2013-06-27	Mahmut Bilgic	Formulations comprising quetiapine fumarate
WO2013100879A1 (en)	2011-12-27	2013-07-04	Mahmut Bilgic	Pharmaceutical compositions comprising quetiapine
US20150018362A1 (en)	2012-02-27	2015-01-15	Biovista, Inc.	Compositions and methods for treating mitochondrial diseases
JP6440625B2 (ja)	2012-11-14	2018-12-19	ザ・ジョンズ・ホプキンス・ユニバーシティー	精神分裂病を処置するための方法および組成物
EP2848244A1 (de)	2013-09-16	2015-03-18	Yildiz Özsoy Erginer	Tablettenformulierungen mit verzögerter Freisetzung aus Quetiapin
AU2014368961B2 (en)	2013-12-20	2019-10-17	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN104016945B (zh) *	2014-05-27	2016-06-29	渭南畅通药化科技有限公司	一种半富马酸喹硫平的制备方法
EP3310785B1 (de)	2015-06-19	2024-11-20	Agenebio, Inc.	Benzodiazepinderivate, zusammensetzungen und verfahren zur behandlung kognitiver beeinträchtigung
US20180170941A1 (en)	2016-12-19	2018-06-21	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en)	2016-12-19	2022-11-22	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
MX2020013927A (es)	2018-06-19	2021-03-02	Agenebio Inc	Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo.
WO2020025579A1 (en)	2018-07-31	2020-02-06	Medichem, S.A.	Solid dosage form of quetiapine fumarate
EP4213817A1 (de)	2020-09-21	2023-07-26	Sun Pharmaceutical Industries Limited	Multipartikuläre pharmazeutische zusammensetzung von quetiapin
CN113698363A (zh) *	2021-09-15	2021-11-26	苏州敬业医药化工有限公司	一种11-哌嗪-二苯并[b,f][1,4]硫氮杂卓盐酸盐的纯化方法
WO2024039886A1 (en)	2022-08-19	2024-02-22	Agenebio, Inc.	Benzazepine derivatives, compositions, and methods for treating cognitive impairment
WO2025172499A1 (en)	2024-02-15	2025-08-21	Itf Research Pharma, S.L.U	Quetiapine liquid formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3389139A (en) *	1963-06-14	1968-06-18	Wander Ag Dr A	6-homopiperazino and piperazinomorphanthridines
FR127F (de) *	1964-03-27
FR90378E (de) *	1965-03-26	1968-02-14
US3539573A (en) *	1967-03-22	1970-11-10	Jean Schmutz	11-basic substituted dibenzodiazepines and dibenzothiazepines
CH539044A (de) *	1967-10-06	1973-08-31	Gnii Orch Poluproduktov I Kras	Verfahren zur Herstellung quaternärer Ammoniumsalze von 1,3-Bis-(aminomethyl)-imidazolidonen
US3928356A (en) *	1967-10-06	1975-12-23	Fujisawa Pharmaceutical Co	10-{8 4-({107 -Hydroxy alkyl)-1-piperazimyl{9 -dibenzo (h,f) oxofins and thiepins and acetyl esters thereof
GB1262509A (en) *	1969-06-20	1972-02-02	Science Union & Cie	New tricyclic derivatives and process for their preparation
CA918659A (en) *	1969-07-31	1973-01-09	Yoshitomi Pharmaceutical Industries	11-(4-substituted-1-piperazinyl)-dibenzo (b,f) (1,4) thiazepines
BE787249A (fr) *	1971-08-05	1973-02-05	Squibb & Sons Inc	Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation
BE792426A (fr) *	1971-12-09	1973-06-07	Wander Ag Dr A	Nouveaux derives de la dibenzo(b,f)(1,4)thiazepine, leur preparation etleur application comme medicaments
US3962248A (en) *	1972-04-04	1976-06-08	Sandoz, Inc.	Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
CH569731A5 (de) *	1972-04-04	1975-11-28	Wander Ag Dr A
CH624682A5 (de) *	1976-11-10	1981-08-14	Sandoz Ag
US4096261A (en) *	1977-02-23	1978-06-20	Abbott Laboratories	Dibenzodiazepines
US4097597A (en) *	1977-02-23	1978-06-27	Abbott Laboratories	Dibenzo b,e! 1,4!diazepines

1986
- 1986-03-27 GB GB868607684A patent/GB8607684D0/en active Pending
1987
- 1987-03-16 IE IE70087A patent/IE59864B1/en not_active IP Right Cessation
- 1987-03-16 FI FI871137A patent/FI86059C/fi not_active IP Right Cessation
- 1987-03-16 PH PH35028A patent/PH26516A/en unknown
- 1987-03-17 ZA ZA871940A patent/ZA871940B/xx unknown
- 1987-03-17 DD DD87300862A patent/DD259403A5/de unknown
- 1987-03-18 IL IL81923A patent/IL81923A/xx not_active IP Right Cessation
- 1987-03-19 MW MW20/87A patent/MW2087A1/xx unknown
- 1987-03-20 AU AU70459/87A patent/AU593336B2/en not_active Expired
- 1987-03-20 US US07/028,473 patent/US4879288A/en not_active Expired - Lifetime
- 1987-03-24 EP EP87302539A patent/EP0240228B1/de not_active Expired - Lifetime
- 1987-03-24 DE DE2000175017 patent/DE10075017I1/de active Pending
- 1987-03-24 AT AT87302539T patent/ATE58132T1/de active
- 1987-03-24 ZW ZW57/87A patent/ZW5787A1/xx unknown
- 1987-03-24 DE DE2000175016 patent/DE10075016I2/de active Active
- 1987-03-24 DE DE8787302539T patent/DE3765969D1/de not_active Expired - Lifetime
- 1987-03-24 ZM ZM29/87A patent/ZM2987A1/xx unknown
- 1987-03-24 ES ES87302539.9T patent/ES2019379T4/es not_active Expired - Lifetime
- 1987-03-24 GB GB878706949A patent/GB8706949D0/en active Pending
- 1987-03-26 NO NO871267A patent/NO168771C/no not_active IP Right Cessation
- 1987-03-26 PT PT84569A patent/PT84569B/pt unknown
- 1987-03-26 NZ NZ219788A patent/NZ219788A/xx unknown
- 1987-03-27 HU HU871342A patent/HU201062B/hu unknown
- 1987-03-27 KR KR1019870002852A patent/KR900001868B1/ko not_active Expired
- 1987-03-27 DK DK198701585A patent/DK174618B1/da not_active IP Right Cessation
- 1987-03-27 AR AR87307138A patent/AR242198A1/es active
- 1987-03-27 CA CA000533171A patent/CA1288428C/en not_active Expired - Lifetime
- 1987-03-27 JP JP62071962A patent/JPH064606B2/ja not_active Expired - Lifetime
1990
- 1990-11-08 GR GR90400276T patent/GR3001061T3/el unknown
1993
- 1993-08-19 HK HK853/93A patent/HK85393A/en not_active IP Right Cessation
1994
- 1994-01-14 CY CY170694A patent/CY1706A/xx unknown
- 1994-01-24 BG BG098406A patent/BG61365B2/bg unknown
1998
- 1998-07-27 NL NL980022C patent/NL980022I2/nl unknown
- 1998-10-30 CY CY1998045C patent/CY98045I2/el unknown
2000
- 2000-06-07 LU LU90593C patent/LU90593I2/fr unknown
2001
- 2001-06-07 NO NO2001009C patent/NO2001009I1/no unknown

Also Published As

Publication number	Publication date
GB8706949D0 (en)	1987-04-29
PT84569A (en)	1987-04-01
MW2087A1 (en)	1987-11-11
NO871267D0 (no)	1987-03-26
EP0240228B1 (de)	1990-11-07
KR870008879A (ko)	1987-10-21
ES2019379B3 (es)	1991-06-16
NO168771C (no)	1992-04-01
IE59864B1 (en)	1994-04-20
NO2001009I1 (no)	2001-06-25
ES2019379T4 (es)	2015-08-12
ATE58132T1 (de)	1990-11-15
PT84569B (pt)	1989-11-30
DE10075017I1 (de)	2000-09-21
ZW5787A1 (en)	1988-11-02
AR242198A1 (es)	1993-03-31
KR900001868B1 (ko)	1990-03-26
DD259403A5 (de)	1988-08-24
DK174618B1 (da)	2003-07-21
LU90593I2 (fr)	2000-08-07
IL81923A (en)	1991-03-10
DK158587D0 (da)	1987-03-27
NL980022I1 (nl)	1998-10-01
AU7045987A (en)	1987-10-01
HUT47568A (en)	1989-03-28
CY1706A (en)	1994-01-14
EP0240228A1 (de)	1987-10-07
FI871137A0 (fi)	1987-03-16
CY98045I1 (el)	2010-07-28
CA1288428C (en)	1991-09-03
US4879288A (en)	1989-11-07
AU593336B2 (en)	1990-02-08
CY98045I2 (el)	2010-07-28
DE3765969D1 (en)	1990-12-13
IL81923A0 (en)	1987-10-20
FI871137L (fi)	1987-09-28
ZM2987A1 (en)	1991-02-28
HU201062B (en)	1990-09-28
NZ219788A (en)	1990-02-26
IE870700L (en)	1987-09-27
DK158587A (da)	1987-09-28
GB8607684D0 (en)	1986-04-30
BG61365B2 (bg)	1997-06-30
FI86059C (fi)	1992-07-10
ZA871940B (en)	1987-11-25
JPH064606B2 (ja)	1994-01-19
NO871267L (no)	1987-09-28
DE10075016I2 (de)	2002-10-10
GR3001061T3 (en)	1992-03-20
NL980022I2 (nl)	1998-11-02
JPS638378A (ja)	1988-01-14
NO168771B (no)	1991-12-23
HK85393A (en)	1993-08-27
FI86059B (fi)	1992-03-31

Publication	Publication Date	Title
US4879288A (en)	1989-11-07	Novel dibenzothiazepine antipsychotic
DE69528704T2 (de)	2003-06-12	Lipidsenkende 1,4-benzothiazepin-1,1-dioxide
WO1993016055A1 (en)	1993-08-19	Hypolipidaemic benzothiazepine compounds
US5008280A (en)	1991-04-16	2-iminobenzothiazoline derivatives, their preparation and pharmaceutical compositions containing them
US4749703A (en)	1988-06-07	Calcium antagonist piperazine derivatives, and compositions therefor
US4588725A (en)	1986-05-13	2-piperazinyl-quinazoline derivatives and pharmaceutical compositions containing them
CZ325196A3 (en)	1997-06-11	Derivatives of hydroximic acid, pharmaceutical compositions containing thereof, process of their preparation and intermediates used in the preparation process
US4237135A (en)	1980-12-02	2-(4-Ethyl-1-piperazinyl)-4-phenylquinoline, process for preparation thereof, and composition thereof
DK170047B1 (da)	1995-05-08	Med basiske heterocycliske grupper substituerede 5-halogen-thienoisothiazol-3(2H)-on-1,1-dioxider og salte deraf, fremgangsmåde til fremstilling af sådanne forbindelser, farmaceutiske præparater indeholdende disse forbindelser og forbindelsernes anvendelse ved fremstilling af lægemidler til behandling af angsttilstande
US5071849A (en)	1991-12-10	Dihydropyrimidothiazine derivatives
US6391870B2 (en)	2002-05-21	Pyrrolo [2,1-b][1,3]benzothiazepines with atypical antipsychotic activity
NZ280192A (en)	1996-02-27	Substituted arylmethyl piperazine derivatives and medicaments
SK1302003A3 (en)	2003-05-02	Pyrrolo[2,1-b][1,3]benzothiazepines and their use for the preparation of medicaments with antipsychotic activity
HU200991B (en)	1990-09-28	Process for production of derivatives of 7-(diphenil-methilen)-bicycloheptane and medical compositions containing them
HU225327B1 (en)	2006-09-28	Pyrrolo[2,1-b][1,3]benzothiazepines and their use for the preparation of medicaments with antipsychotic activity
CS209917B2 (cs)	1981-12-31	Způsob přípravy (omega-aminoalkoxy) bibanzylů
HK1036793B (en)	2003-05-09	Pyrrolo [2,1-b][1,3]benzothiazepines with atypical antipsychotic activity
CS240041B1 (cs)	1986-02-13	4-(2-Chlor-10, ll-dihydrodibenzo/b,f/thiepin-ll-yl) piperazinoalkyl-ethery a -sulfidy, jakož i jejich soli